显示标签为“cure”的博文。显示所有博文
显示标签为“cure”的博文。显示所有博文

2013年9月18日星期三

Gene Therapy: A Cure for Canine Diabetes











Beagle dog, from Wikipedia commons

Treatment of Diabetes and Long-term Survival Following Insulin and Glucokinase Gene Therapy




David Callejas, Christopher J. Mann, Eduard Ayuso, Ricardo Lage, Iris Grifoll, Carles Roca, Anna Andaluz, Rafael Ruiz-de Gopegui, Joel Montané, Sergio Muñoz, Tura Ferre, Virginia Haurigot, Shangzhen Zhou, Jesús Ruberte, Federico Mingozzi, Katherine A. High, Felix Garcia, and Fatima Bosch

Diabetes (Published online before print) February 1, 2013, doi:10.2337/db12-1113





In both man and dogs, diabetes is a chronic disease for which there is no cure. Almost all diabetic dogs need insulin replacement therapy to survive, but glycemic control is never perfect (1-3). Therefore, long-term complications of diabetes (e.g., cataracts) disease are frequently observed (4-6). In addition, burden of our traditional treatment methods takes a toll on the owners of diabetic pets and results in a proportion of pets being euthanized instead of being treated (7). If pet owners do decide to treat their diabetic pets, they commonly report a significant treatment burden, with a number of negative effects on various aspects of the pet’s and owner’s lifestyle (7,8).



Gene therapy for diabetes
Obviously, a less arduous treatment option for controlling diabetes mellitus in dogs would be welcomed.  Gene therapy has the potential to provide this alternative method of treatment for animals as well as for humans. Simplistically, in gene therapy, particular strings of DNA are “inserted” into cells such that the machinery of the cell takes the DNA, transcribes it into RNA, and then makes the protein that is encoded in the new DNA. This technique allows us to force cells to make proteins that they might not otherwise make, and in the last decade it has started to see success in small trials to treat a number of diseases.


As it turns out, however, designing and targeting a string of DNA at a cell is not easy (8,9). Currently, most investigators use what is called viral vectors to get the DNA inside cells— basically, this involves taking a virus that contains the DNA we want to insert, and infect cells with the virus. The virus enters the cell, where it can integrate its DNA segment into the chromosomes of the host cell (8).


For diabetes, experimental gene therapy has generally involved injection of protein-coding genes into skeletal muscle or the liver. This exploits these tissues’ intrinsic ability to read such genes and subsequently constitutively produce the corresponding protein, which is then secreted into the general circulation by virtue of the extensive vascularization of peripheral muscles (10-14).


Study reporting successful gene therapy for canine diabetes
To date, most gene therapy has involved studies in diabetic mice. As reported by Callejas et al. in the  journal Diabetes (15), these researchers from the Center of Animal Biotechnology and Gene Therapy, Universitat Autonoma de Barcelona, Spain, used gene therapy to treat and “cure” 5 Beagle dogs with insulin-deficient diabetes.


This same research group had already tested this type of therapy on mice (10), but the excellent results obtained for the first time with large animals lays the foundation for the clinical translation of this gene therapy approach to veterinary medicine and eventually for diabetic human patients.


The diabetic state in these dogs had been induced by injection of a mixture of streptozotocin and alloxan, both of which are toxic to beta cells (16). After becoming diabetic, the dogs were treated with one of the following:



  1. Insulin glargine, administered twice daily

  2. Intramuscular injection of the glucokinase gene alone 

  3. Intramuscular injection of the insulin gene alone

  4. Intramuscular injection of both the insulin and glucokinase genes. 


Not surprisingly, without treatment, the dogs were markedly hyperglycemic. The dogs on twice daily insulin were better controlled but remained hyperglycemic.


To test both the insulin and glucose kinase vectors together, the researchers injected 5 dogs with one or two doses of the viral vectors. These dogs quickly regained normoglycemia, and even the higher doses were tolerated well; none of the dog had any side effects. Unlike the dogs given insulin alone, the dogs given both genes together responded much better to an oral glucose tolerance test, spiking slightly up to between 200 and 300 mg/dL, but stayed well below the levels seen with the diabetic dogs.


The dogs gained weight, had lower serum fructosamine levels, and experienced long-term remission of the diabetes without secondary complications. Therapy that included only the insulin gene or the glucose kinase gene but not both did not result in the same level of success.


Click here to see a video of the treated dogs in diabetic remission.


My Bottom Line:


Since the 1922 breakthrough discovery of Banting and Best (17), who corrected hyperglycemia in dogs using pancreatic extracts, exogenous insulin administration has been the mainstay of diabetes therapy (1-3). Alternative therapies have been studied, but thus far only a handful of approaches, mainly involving allo- or xeno-transplantation of pancreatic islets, have reached clinical application (18).


The authors of this landmark study (15) took a different approach: instead of trying to transplant or manufacture beta cells that respond to glucose and produce insulin, they used dual gene therapy to develop a “glucose sensor” in skeletal muscle that permitted long-term, normoglycemia in this canine model of diabetes.


The gene therapy used in these dogs consisted of a single session of intramuscular injections to introduce gene therapy vectors, with two ultimate objectives: to express the insulin gene, on the one hand, and that of glucokinase, on the other. Glucokinase is an enzyme that regulates the uptake of glucose from the blood (19). When both insulin and glucokinase genes act simultaneously, they function together as a glucose sensor to automatically regulate the uptake of glucose from the blood, thus reducing hyperglycemia (20).





The results of this study look very promising indeed. The dogs in the study, once treated, experienced long-term normoglycemia, both in the fasting or fed state, with no need for exogenous insulin therapy. There were no episodes of hypoglycemia, even after the dogs were exercised. In addition, all dogs regained lost body weight and developed no secondary complications 4 years after treatment.



Hopefully, this study will provide the basis for the initiation of clinical studies in dogs (and cats?) with naturally-occurring diabetes. Such veterinary clinical trials should also help investigators in preparing for the use of this approach in humans patients with diabetes.  


References:



  1. Davison LJ, Herrtage ME, Catchpole B. Study of 253 dogs in the United Kingdom with diabetes mellitus. Vet Rec 2005;156:467-471.

  2. Nelson RW. Canine diabetes mellitus In: Ettinger SJ, Feldman EC, eds. Textbook of Veterinary Internal Medicine: Diseases of the Dog and Cat. Seventh ed. St. Louis: Saunders Elsevier, 2010;1449-1474.

  3. Davison LJ. Canine diabetes mellitus In: Mooney CT, Peterson ME, eds. BSAVA Manual of Canine and Feline Endocrinology. Fourth ed. Quedgeley, Gloucester: British Small Animal Veterinary Association, 2012;116-132.

  4. Munana KR. Long-term complications of diabetes mellitus, Part I: Retinopathy, nephropathy, neuropathy. Vet Clin North Am Small Anim Pract 1995;25:715-730. 

  5. Basher AW, Roberts SM. Ocular manifestations of diabetes mellitus: diabetic cataracts in dogs. Vet Clin North Am Small Anim Pract 1995;25:661-676. 

  6. Beam S, Correa MT, Davidson MG. A retrospective-cohort study on the development of cataracts in dogs with diabetes mellitus: 200 cases. Vet Ophthalmol 1999;2:169-172. 

  7. Niessen SJ, Powney S, Guitian J, et al. Evaluation of a quality-of-life tool for dogs with diabetes mellitus. J Vet Intern Med 2012;26:953-961. 

  8. Bertolaso M, Olsson J, Picardi A, et al. Gene therapy and enhancement for diabetes (and other diseases): the multiplicity of considerations. Diabetes Metab Res Rev 2010;26:520-524. 

  9. Alenzi FQ, Lotfy M, Tamimi WG, et al. Review: Stem cells and gene therapy. Lab Hematol 2010;16:53-73. 

  10. Mas A, Montane J, Anguela XM, et al. Reversal of type 1 diabetes by engineering a glucose sensor in skeletal muscle. Diabetes 2006;55:1546-1553.  

  11. Wong MS, Hawthorne WJ, Manolios N. Gene therapy in diabetes. Self Nonself 2010;1:165-175. 

  12. Bagley J, Paez-Cortez J, Tian C, et al. Gene therapy in type 1 diabetes. Crit Rev Immunol 2008;28:301-324. 

  13. Niessen SJ, Fernandez-Fuente M, Mahmoud A, et al. Novel diabetes mellitus treatment: mature canine insulin production by canine striated muscle through gene therapy. Domest Anim Endocrinol 2012;43:16-25. 

  14. Ren B, O’Brien BA, Byrne MR, et al. Long-term reversal of diabetes in non-obese diabetic mice by liver-directed gene therapy. J Gene Med 2013;15:28-41. 

  15. Callejas D, Mann CJ, Ayuso E, et al. Treatment of diabetes and long-term survival following insulin and glucokinase gene therapy. Diabetes 2013 (in press). 

  16. Anderson HR, Stitt AW, Gardiner TA, et al. Induction of alloxan/streptozotocin diabetes in dogs: a revised experimental technique. Lab Anim 1993;27:281-285. 

  17. Banting FG, Best CH, Collip JB, et al. Pancreatic extracts in the treatment of diabetes mellitus. Can Med Assoc J 1922;12:141-146. 

  18. Robertson RP. Islet transplantation a decade later and strategies for filling a half-full glass. Diabetes 2010;59:1285-1291.  

  19. Printz RL, Magnuson MA, Granner DK. Mammalian glucokinase. Annu Rev Nutr 1993;13:463-496. 

  20. Otaegui PJ, Ferre T, Pujol A, et al. Expression of glucokinase in skeletal muscle: a new approach to counteract diabetic hyperglycemia. Hum Gene Ther 2000;11:1543-1552. 


Possible Diabetes Cure Ignored by "Big Pharma"



February 14, 2009



Possible Diabetes Cure Ignored by “Big Pharma”




stem cells, adult stem cells, diabetes, type 1 diabetes, juvenile diabetes


Twelve years ago, Professor Irving Weissman discovered a treatment that could have saved the lives of thousand of women with advanced breast cancer. Pharmaceutical companies weren’t interested in developing the therapy at the time.


Though interest in his methods are finally being ignited, Weissman regrets the wasted time. In a set of lectures, Weissman repeatedly expressed frustration that while many of his discoveries in the field of stem cell research seemed to hold remarkable potential for life-saving treatments, commercial or regulatory hurdles have prevented his scientific findings from benefiting patients.


One example is Weissman’s research on type I diabetes, in which he demonstrated the ability to fully cure type I diabetes in mice using stem cells. But even though his experiments avoided political controversy by using adult stem cells, which do not come from embryos, Weissman ran into a road block when pharmaceutical companies refused to sponsor clinical trials.


Weissman believes that the pharmaceutical companies put profit over principle, preferring to keep diabetes sufferers dependent on costly insulin than to cure them once and for all.








Dr. Mercola’s Comments:



Type 1 diabetes, or insulin dependent diabetes, is a really sad chronic condition. This is in stark contrast to


type 2, which is caused by insulin resistance and faulty leptin signaling, due to inappropriate diet and lack of exercise – an entirely preventable, and nearly 100 percent reversible condition through lifestyle modifications.


Type 1 diabetics, however, do not produce insulin and must therefore inject insulin several times a day. The disease tends to progress rather quickly and therefore needs to be diagnosed early, as it can result in serious long-term complications including blindness, kidney failure, heart disease and stroke.


Tragically those with type 1 diabetes can have the healthiest lifestyle possible yet still suffer many diseases, as current technology is a poor substitute for a fully functioning pancreas. The sad thing about type 1 diabetes is that it now appears nearly completely preventable.  New research suggests if a pregnant woman has optimal vitamin D levels during her pregnancy and then maintains them in her baby once delivered, this should radically reduce if not virtually eliminate type 1 diabetes.


Obviously finding out this information after a person has had their pancreatic islet cells destroyed and is insulin dependent doesn’t help much, but the good news is that within your lifetime we will have developed the ability to safely replace these cells, most likely with similar approaches to the one described in the article above.


If this sounds farfetched, you should know that Dr. Weissman is not the only scientist to lay claim to the power of stem cells to cure type 1 diabetes.


In 2007 the British Times Online reported on the first clinical evidence for the efficacy of Hematopoietic stem cells (stem cells derived from bone marrow) in type 1 diabetes.


The Brazilian study, published in Journal of the American Medical Association (JAMA), found that treatment-related toxicity was low, with zero mortality. All but two of the volunteers (93 percent) in the trial did not require daily insulin injections for up to three years after the end of their treatment, as the therapy allowed their bodies to start producing the hormone naturally again.


The main drawback with the particular therapy used in that study, from my standpoint, is that drugs were used to first suppress the patients’ immune system before receiving transfusions of stem cells drawn from their own blood. Suppression of your immune system could lead to all types of health problems – after all, your immune system is your primary line of defense – however, the theory of using stem cells to reactivate natural insulin production is an intriguing and hopeful one.


Does Big Pharma Want to Find a Cure for Diabetes?


It certainly would not make financial sense, and I think it’s fairly safe to say that pharmaceutical companies are in business these days to make money – not to actually cure disease. So, when Dr. Weissman implies that he was unable to entice pharmaceutical sponsors because they prefer to keep diabetes sufferers dependent on costly insulin, he’s probably not far off.


There are numerous examples of well-educated, innovative doctors and scientists who have created alternative medical treatments that far supersede conventional drug treatments, and yet they are more frequently than not shunned, persecuted, or even prosecuted for their efforts.


At least Dr. Weissman did not suffer a fate similar to any of these doctors:




  • Gaston Naessens – Dr. Naessens cancer treatment is based on the theory that cancer is caused by a friendly microorganism called somatids (“little bodies”) — which are present in all cells — that becomes unfriendly. His formula, 714X, provides nitrogen to the cancer cells, thus causing this microorganism to cease excreting their toxic compounds, and mobilize your immune system to kill the cancer cells. He was subsequently put on trial for his cancer discoveries.

  • Stanislaw Burzynski — Dr. Burzynski, founder of the Houston-based Burzynski Institute, treats cancer patients with substances called antineoplastons. He was indicted by a grand jury in 1995 for his use of antineoplastons– his second trial that year. He was acquitted.


  • Ryke Geerd Hamer – Dr. Hamer’s “German New Medicine” (GNM), operates under the premise that every disease originates from an unexpected shock experience, and that all disease can be cured by resolving these underlying emotional traumas. Despite a 95 percent success rate, Dr. Hamer has spent time in prison for refusing to disavow his medical findings and stop treating his patients with his unorthodox techniques, and is currently living in exile, seeking asylum from persecution.


Adult Stem Cell Treatments are the Wave of the Future


I believe therapies using adult stem cells – as opposed to embryonic stem cells which are at the heart of the stem cell controversy – is and will continue to be a major, exciting part of the future of medicine.


There’s little risk of rejection when using your own adult stem cells, so you’re less likely to need dangerous immunosuppressive drugs. And besides certain ethical issues and regulatory barriers to embryonic stem cell therapy, adult stem cells may hold several technical advantages. For one, they may be more viable.


It’s a little known fact that only about 30 percent of conceptions advance to term. In other words, about 70 percent of embryos may be so defective that they naturally abort.


In addition to eventually helping restore internal organs, immune systems and more, adult stem cell therapies also hold the promise of restoring old skin and bald scalps. I am personally beta testing a new product for regrowing hair that has adult stem cell factors (primarily peptides, no DNA)  and have been favorably impressed with the results to date.


One major player in the field is The Maximum Life Foundation. They have discovered an emerging technology that could fine tune stem cell treatments and make every adult stem cell therapy in the world much more safe and effective.


As you age, your stem cells diminish in quality and quantity, so just when you require strong stem cells the most, you’re becoming deficient. Hence your organs and tissues eventually wear out and need to be restored or replaced.


Cells become randomly damaged or mutated over time, but a small percentage may incur relatively little damage—or may escape damage altogether. So some of your stem cells may be as pristine as those that you enjoyed as a teenager, or even as an infant.


The technology discovered by The Maximum Life Foundation identifies, isolates, and amplifies those “pristine” stem cells from your own population for therapies. This selection process could supercharge stem cell treatments by using these “best of breed” cells instead of old cells.


Stem Cell Treatments Have Been Proven to Work


As a bridge to human therapies, a San Diego company has already given us a peek into the future with their horse and dog treatments. Vet-Stem provides a quick-turnaround laboratory service that lets veterinarians to use regenerative cells in animals.


The veterinarian simply collects a small fat sample from the patient and ships it overnight to the Vet-Stem laboratory. Then, Vet-Stem processes the sample, concentrates the cells which are shipped in ready-to-inject syringes. Finally, the veterinarian injects the cells directly into the injured site.


With more than 3,000 horses treated and multiple studiesdemonstrating the success and safety of their regenerative medicine, Vet-Stem currently helps horses and dogs with fractures, joint disease, or tendon or ligament injuries return to their full level of ability.


Just imagine what the prospects for aged humans might be if similar treatments used pristine human stem cells. Type 1 diabetes wouldn’t be the only chronic disease that could be effectively wiped out.


However, despite Dr. Weissman’s negative experiences in trying to bring his findings to the fore, it’s not completely out of the question yet. In an accompanying editorial in JAMA titled “Cellular therapy for type 1 diabetes: has the time come?”Dr Jay Skyler of the Diabetes Research Institute at the University of Miami, wrote:


“Research in this field is likely to explode in the next few years and should include randomized controlled trials, as well as mechanistic





No comments yet.


RSS feed for comments on this post. TrackBack URI



2013年9月17日星期二

We Are The Cure Blog

Every one out of four individuals is affected by diabetes. The disease, mainly characterized by insulin deficiency is predominant among middle aged adults and sometimes among children. It is surprising to know that even our pets cannot escape the pitfalls of the diabetes.


The disease, scientifically known as diabetes mellitus often stems out of pancreatic inflammation and is often characterized by weight loss, increased thirst and urination, appetite and liver malfunction. This at a later stage may lead to chronic infection, vomiting and even dehydration in dogs. If we dig into deep, insulin is one of the main hormones which have a key role in the metabolism process and its reduced secretion harms smooth functioning of the digestive track.


In order to diagnose whether your dog has been affected by the disease, vets recommend a complete blood count, urine analysis. Presence of Ketones indicates diabetes complications which need to be handled with immediate care. However, treatment of insulin is not really tough. Once your dog has been diagnosed with diabetes, he needs to go through a blood curve taste. The blood curve taste helps the veterinarian to identify the kind of diet that would be appropriate to decrease his blood sugar levels. You need to be precautious that your dog is under the strict diet as prescribed by the practitioner. Once your dog is catered with proper rest, sleep and diet, beating the diabetic blue is only a few steps away!

2013年9月15日星期日

Perhaps a cure for type one diabetes in dogs

Interesting post here about a study which resulted in long-term remission of type one diabetes in dogs.